Valeant Pharmaceuticals reported $362M in Interest Expense on Debt for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Amgen AMGN:US $ 295M 40M
Ani Pharmaceuticals ANIP:US $ 6.61M 2.17M
Aurora Cannabis Inc ACB:CN 25.8M 9.89M
Biogen BIIB:US $ 66.1M 0.2M
Bristol Myers Squibb BMY:US $ 326M 3M
Catalent CTLT:US $ 33M 1M
Danaher DHR:US $ 54M 2M
Eli Lilly And LLY:US $ 84.9M 3.5M
Endo International Ordinary Shares ENDP:US $ 135.07M 8.53M
Gilead Sciences GILD:US $ 238M 0M
JAZZ PHA JAZZ:US $ 70.88M 17.81M
Lannett LCI:US $ 14.52M 0.09M
Nektar Therapeutics NKTR:US $ 7.53M 0.6M
Pacira Pharmaceuticals PCRX:US $ 10.25M 0.18M
Phibro Animal Health PAHC:US $ 3.11M 0.01M
Prestige Brands PBH:US $ 15.97M 0.95M
Revance Therapeutics RVNC:US $ 1.93M 358K
Supernus Pharmaceuticals SUPN:US $ 1.16M 3.95M
Valeant Pharmaceuticals VRX:CN $ 362M 16M
Vertex Pharmaceuticals VRTX:US $ 14.9M 0.19M
Zoetis ZTS:US $ 53M 1M